Medical Devices Startups
6,513 companies tagged Medical Devices, with their investors and founders.
Promedius offers an AI-powered diagnostic tool that analyzes chest X-rays to detect osteoporosis and assess bone health for clinicians and patients. The platform uses deep learning algorithms to automatically identify at-risk patients and generate clinical reports integrated into existing hospital imaging systems.
1 investor
Oncolys develops viral therapy drugs and treatments for cancer and severe viral infections, with a focus on oncolytic viruses and rare diseases. The company operates a hybrid business model combining licensing partnerships with pharmaceutical firms and direct commercialization of its own therapies.
1 investor
Kolagen Pharma develops and sells pharmaceuticals, medical devices, and research reagents, and manufactures cosmetics, focusing on collagen-based biomaterials for regenerative medicine. Founded by university researchers in science and pharmacology, it is based within Kyoto University's medical research facilities in Japan.
1 investor
CellGen Tech develops cell-based medicines for rare and intractable diseases by engineering human adipose cells to produce therapeutic proteins. The company focuses on treating conditions caused by missing or deficient enzymes and proteins, with partnerships involving university medical experts.
1 investor
Cellspect develops next-generation clinical diagnostic reagents and in-vitro diagnostic products based on deep-tech, covering diagnostic technologies from biomarker discovery to treatment monitoring. It offers open-innovation partnerships with pharmaceutical companies and medical institutions, including point-of-testing and precision oncology products, based in Iwate, Japan.
1 investor
T Cell Nouveau develops Hybrid CAR-T cell therapies designed to treat solid tumors by enhancing immune system activation in suppressive tumor microenvironments. The clinical-stage biopharmaceutical company targets cancer patients and originated from research conducted at Mie University's Personalized Cancer Immunotherapy department.
1 investor
Tokiwa Bio develops the Stealth-type RNA vector (SRV™), a non-integrating gene delivery vector that can introduce multiple or large genes into cells at high efficiency for gene therapy. The company also applies SRV™ to cell reprogramming for regenerative medicine and to biopharmaceutical manufacturing.
1 investor
A digital solutions company providing medical and healthcare information access for physicians, healthcare institutions, and pharmaceutical companies in Japan.
1 investor
Human Life Code develops and commercializes novel therapeutics in specialty care areas such as cancer, autoimmune diseases, and retinal diseases. The company specializes in research, development, market launch, and lifecycle management of pharmaceutical products and regenerative medicine products.
1 investor
PharmaBio is Japan's first contract development and manufacturing organization (CDMO) for regenerative medicine and cell-based therapeutics. The company provides regulatory development support and manufacturing services for cell and tissue-derived pharmaceuticals.
1 investor
Physiologas develops technology to innovate healthcare and improve patient and family wellbeing. The company operates in the medical technology sector, based in Japan.
1 investor
Kamui Pharma develops therapeutic compounds derived from probiotics for treating inflammatory bowel disease and other diseases. The company conducts drug discovery research and clinical trials focused on novel bioactive molecules.
1 investor
A company with expertise in developing pharmaceutical products through clinical trial phases (IND to NDA/BLA) and launching them for patients in Japan and Asia.
1 investor
Port Corporation operates internet media platforms and services across recruitment, finance, healthcare, energy, and real estate sectors in Japan. The company provides job search platforms, telehealth services, financial information portals, and energy comparison services.
1 investor
PorMedTec develops transplantable organs and tissues using genetically modified pigs for manufacturing and commercializing as regenerative medicine products. The company targets patients and healthcare systems facing severe organ shortages by providing alternatives to dialysis and other symptom-based treatments.
1 investor
MiRNDa, Inc. is a Japanese biotech company developing in-vitro diagnostic (IVD) medical devices based on RNA modification technology to detect an early "stage 0" of cancer.
1 investor
Medeta develops AI and digital technology solutions to expand reproductive medicine techniques and services, making them reproducible and accessible to patients. The company applies artificial intelligence to fertility treatment workflows to enhance physician and embryologist expertise.
1 investor
Melody International develops mobile fetal and maternal monitoring medical devices, including the "iCTG" cardiotocograph and the "Central i" central monitoring system for perinatal care. The Japanese company provides remote maternal and fetal health monitoring for healthcare providers, with device registrations in Japan and international markets such as Thailand, Kenya, the Philippines, and Indonesia.
1 investor
United Immunity develops a myeloid-targeting platform using pullulan-based nanoparticles to selectively deliver therapeutic agents and vaccine antigens to macrophages and dendritic cells. The platform targets these immune cells through DC-SIGN receptor binding for cancer immunotherapy, vaccines, and treatment of fibrosis, viral infections, and inflammatory diseases.
1 investor
A company developing radioactive pharmaceuticals for cancer treatment with enhanced visibility. The company focuses on accelerating the delivery of innovative diagnostic and therapeutic agents to patients and healthcare providers.
1 investor
TaiMed Biologics is a Taiwan-based biopharmaceutical company that develops monoclonal antibody therapies for HIV, including the long-acting TMB-365/TMB-380 combination and the CD4-targeted ADC platform extending into autoimmune diseases. It also operates a cGMP protein manufacturing facility and provides CDMO services such as process development, analytical method development, formulation development, and commercial manufacturing for antibody products.
1 investor
Yasojima Proceed manufactures and sells high-performance resin components through machining services, as well as advanced materials for 3D printing and industrial applications. The company serves automotive, aerospace, medical, robotics, and semiconductor industries with material solutions and 3D technology services.
1 investor
A research-driven specialty pharmaceutical company that develops and commercializes innovative medicines through the 505(b)(2) regulatory pathway, focusing on central nervous system disorders, metabolic diseases, and orphan indications. The company operates in New Jersey and Shanghai, leveraging established molecules with proven safety profiles.
1 investor
Pharmaron provides drug research and development services globally, supporting the discovery and development of pharmaceutical therapies through integrated capabilities across multiple geographic regions.
1 investor